Cargando…

Proposal of an Algorithm to Early Detect Attenuated Type I Mucopolysaccharidosis (MPS Ia) among Children with Growth Abnormalities

Background and Objectives: Diagnostic delay is common in attenuated Mucopolysaccharidosis Type I (MPS Ia) due to the rarity of the disease and the variability of clinical presentation. Short stature and impaired growth velocity are frequent findings in MPS Ia, but they rarely raise suspicion as paed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baronio, Federico, Zucchini, Stefano, Zulian, Francesco, Salerno, Mariacarolina, Parini, Rossella, Cattoni, Alessandro, Deodato, Federica, Gaeta, Alberto, Bizzarri, Carla, Gasperini, Serena, Pession, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780542/ https://www.ncbi.nlm.nih.gov/pubmed/35056405 http://dx.doi.org/10.3390/medicina58010097

Ejemplares similares

“Growth patterns in children with mucopolysaccharidosis type I-Hurler after hematopoietic stem cell transplantation: Comparison with untreated patients”
por: Cattoni, Alessandro, et al.
Publicado: (2021)

Open issues in Mucopolysaccharidosis type I-Hurler
por: Parini, Rossella, et al.
Publicado: (2017)

Immunological evaluation of patients with mucopolysaccharidosis (MPS)
por: Aranda, Carolina, et al.
Publicado: (2015)

Safety outcomes and patients’ preferences for home-based intravenous enzyme replacement therapy (ERT) in pompe disease and mucopolysaccharidosis type I (MPS I) disorder: COVID-19 and beyond
por: Toscano, Antonio, et al.
Publicado: (2023)

Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations
por: Parini, Rossella, et al.
Publicado: (2020)

Enzyme replacement therapy: efficacy and limitations
por: Concolino, Daniela, et al.
Publicado: (2018)

Genotype‐phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry
por: Clarke, Lorne A., et al.
Publicado: (2019)

Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry
por: D’Aco, Kristin, et al.
Publicado: (2012)

Parents’ experiences of living with, and caring for children, adolescents and young adults with Mucopolysaccharidosis (MPS)
por: Somanadhan, S., et al.
Publicado: (2016)

Sexual behaviour in a murine model of mucopolysaccharidosis type I (MPS I)
por: Barbosa Mendes, Ana, et al.
Publicado: (2019)

Mucopolysaccharidosis (MPS): Review of the literature and case series of five pediatric dental patients
por: Hirst, Lorna, et al.
Publicado: (2021)

The use of recombinant human growth hormone in patients with Mucopolysaccharidoses and growth hormone deficiency: a case series
por: Cattoni, A., et al.
Publicado: (2019)

Airway Abnormalities in Adult Mucopolysaccharidosis and Development of Salford Mucopolysaccharidosis Airway Score
por: Gadepalli, Chaitanya, et al.
Publicado: (2021)

Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS)
por: Spataro, Federico, et al.
Publicado: (2022)

PReS-FINAL-2244: Ultrasound examination reveals typical alterations in joints of mucopolysaccharidosis (MPS) patients
por: Karabul, N, et al.
Publicado: (2013)

Intrafamilial variability in the clinical manifestations of mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS)
por: Ficicioglu, Can, et al.
Publicado: (2017)

Mucopolysaccharidosis-Plus Syndrome, a Rapidly Progressive Disease: Favorable Impact of a Very Prolonged Steroid Treatment on the Clinical Course in a Child
por: Faraguna, Martha Caterina, et al.
Publicado: (2022)

Targeting a Pre-existing Anti-transgene T Cell Response for Effective Gene Therapy of MPS-I in the Mouse Model of the Disease
por: Squeri, Giorgia, et al.
Publicado: (2019)

Mis-splicing of the GALNS gene resulting from deep intronic mutations as a cause of Morquio a disease
por: Caciotti, Anna, et al.
Publicado: (2018)

A new case report of severe mucopolysaccharidosis type VII: diagnosis, treatment with haematopoietic cell transplantation and prenatal diagnosis in a second pregnancy
por: Furlan, Francesca, et al.
Publicado: (2018)

Mucopolysaccharidosis: Cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI
por: Brands, Marion M. M. G., et al.
Publicado: (2012)

Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network
por: Dornelles, Alícia Dorneles, et al.
Publicado: (2014)

Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: Review and classification of published variants in the ARSB gene
por: Tomanin, Rosella, et al.
Publicado: (2018)

Atypical microbial infections of digestive tract may contribute to diarrhea in mucopolysaccharidosis patients: a MPS I case study
por: Węgrzyn, Grzegorz, et al.
Publicado: (2005)

Growth in individuals with attenuated mucopolysaccharidosis type I during untreated and treated periods: Data from the MPS I registry
por: Polgreen, Lynda E., et al.
Publicado: (2022)

Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y
por: Jones, Simon A., et al.
Publicado: (2015)

Cardiac abnormalities in adults with the attenuated form of mucopolysaccharidosis type I
por: Soliman, O. I. I., et al.
Publicado: (2007)

Skeletal Abnormalities and VDR1 Gene Polymorphisms in Mucopolysaccharidosis Patients
por: Alkhzouz, Camelia, et al.
Publicado: (2021)

Molecular Characterization of a Novel Splicing Mutation Underlying Mucopolysaccharidosis (MPS) Type VI—Indirect Proof of Principle on Its Pathogenicity
por: Coutinho, Maria Francisca, et al.
Publicado: (2020)

Clinical Characteristics and Healthcare Resource Utilization for Patients with Mucopolysaccharidosis II (MPS II) in the United States: A Retrospective Chart Review
por: Ayodele, Olulade, et al.
Publicado: (2022)

Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?
por: Horgan, Claire, et al.
Publicado: (2022)

Easy‐to‐use algorithm would provide faster diagnoses for mucopolysaccharidosis type I and enable patients to receive earlier treatment
por: Tylki‐Szymańska, Anna, et al.
Publicado: (2018)

Orofacial abnormalities in mucopolysaccharidosis and mucolipidosis type II and III: A systematic review
por: de Bode, Chiel J., et al.
Publicado: (2022)

Vagal Nerve Stimulation in the Treatment of Drug-Resistant Epileptic Encephalopathies in Inborn Errors of Metabolism: Report of 2 Cases
por: Grioni, Daniele, et al.
Publicado: (2015)

International working group identifies need for newborn screening for mucopolysaccharidosis type I but states that existing hurdles must be overcome
por: Parini, Rossella, et al.
Publicado: (2018)

Pituitary abnormalities in midline brain defects
por: Zucchini, Stefano
Publicado: (2020)

The Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II)
por: Sampayo-Cordero, Miguel, et al.
Publicado: (2020)

Mucopolysaccharidosis VI
por: Valayannopoulos, Vassili, et al.
Publicado: (2010)

Bisphosphonate Treatment in a Patient Affected by MPS IVA with Osteoporotic Phenotype
por: Tummolo, Albina, et al.
Publicado: (2013)

Treatment of thoracolumbar kyphosis in patients with mucopolysaccharidosis type I: results of an international consensus procedure
por: Kuiper, Gé-Ann, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rsa411kfd0a8h6u8thpta59pru